ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report

ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report

This is a report of 30 years old woman suffering from Crohn’s disease who had a good clinical response to Infliximab (Remicade) at first, but during the treatment after 5 months she lost response. After receiving Adalimumab (Humira) clinical remission was reached on the day 20. The case demonstrates...

Full description

Bibliographic Details
Main Authors: Ivaylo Vazharov, Hristo Bozov, Snezha Zlateva, Georgi Bonchev
Format: Article
Language:English
Published: Peytchinski Publishing 2016-12-01
Series:Journal of IMAB
Subjects:
Crohn's disease
TNF- alpha inhibitors
adalimumab
infliximab
Online Access:http://www.journal-imab-bg.org/issues-2016/issue4/JofIMAB-2016-22-4p1389-1391.pdf
id doaj-ac0bb11062114a6ab4f02eef0ead3777
record_format Article
spelling doaj-ac0bb11062114a6ab4f02eef0ead37772020-11-24T21:40:49ZengPeytchinski PublishingJournal of IMAB1312-773X2016-12-012241389139110.5272/jimab.2016224.1389ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case reportIvaylo Vazharov0Hristo Bozov1Snezha Zlateva2Georgi Bonchev3Clinic of Internal diseases, Naval Hospital – Varna, Military Medical Academy, BulgariaClinic of Anaesthesiology, Marine and Intensive medicine, Naval Hospital – Varna, Military Medical Academy, BulgariaClinic for Intensive Treatment of Acute Intoxications and Toxicoallergies, Naval Hospital – Military Medical Academy, Bulgaria.Clinic for Intensive Treatment of Acute Intoxications and Toxicoallergies, Naval Hospital – Military Medical Academy, Bulgaria.This is a report of 30 years old woman suffering from Crohn’s disease who had a good clinical response to Infliximab (Remicade) at first, but during the treatment after 5 months she lost response. After receiving Adalimumab (Humira) clinical remission was reached on the day 20. The case demonstrates rapid response to adalimumab in incidence of losing efficacy to another tumor necrotic factor - alpha (TNF- alpha) antagonist.http://www.journal-imab-bg.org/issues-2016/issue4/JofIMAB-2016-22-4p1389-1391.pdfCrohn's diseaseTNF- alpha inhibitorsadalimumabinfliximab
collection DOAJ
language English
format Article
sources DOAJ
author Ivaylo Vazharov
Hristo Bozov
Snezha Zlateva
Georgi Bonchev
spellingShingle Ivaylo Vazharov
Hristo Bozov
Snezha Zlateva
Georgi Bonchev
ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
Journal of IMAB
Crohn's disease
TNF- alpha inhibitors
adalimumab
infliximab
author_facet Ivaylo Vazharov
Hristo Bozov
Snezha Zlateva
Georgi Bonchev
author_sort Ivaylo Vazharov
title ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
title_short ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
title_full ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
title_fullStr ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
title_full_unstemmed ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
title_sort adalimumab induction and maintaining remission for crohn’s disease in patient who lost response to infliximab. case report
publisher Peytchinski Publishing
series Journal of IMAB
issn 1312-773X
publishDate 2016-12-01
description This is a report of 30 years old woman suffering from Crohn’s disease who had a good clinical response to Infliximab (Remicade) at first, but during the treatment after 5 months she lost response. After receiving Adalimumab (Humira) clinical remission was reached on the day 20. The case demonstrates rapid response to adalimumab in incidence of losing efficacy to another tumor necrotic factor - alpha (TNF- alpha) antagonist.
topic Crohn's disease
TNF- alpha inhibitors
adalimumab
infliximab
url http://www.journal-imab-bg.org/issues-2016/issue4/JofIMAB-2016-22-4p1389-1391.pdf
work_keys_str_mv AT ivaylovazharov adalimumabinductionandmaintainingremissionforcrohnsdiseaseinpatientwholostresponsetoinfliximabcasereport
AT hristobozov adalimumabinductionandmaintainingremissionforcrohnsdiseaseinpatientwholostresponsetoinfliximabcasereport
AT snezhazlateva adalimumabinductionandmaintainingremissionforcrohnsdiseaseinpatientwholostresponsetoinfliximabcasereport
AT georgibonchev adalimumabinductionandmaintainingremissionforcrohnsdiseaseinpatientwholostresponsetoinfliximabcasereport
_version_ 1725924429853097984

Similar Items